XML 52 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Basic and Diluted Loss Per Share
 12 Months Ended
Dec. 31, 2020
Basic and Diluted Loss Per Share  
Basic and Diluted Loss Per Share

Note 11. Basic and Diluted Loss Per Share

Basic loss per share is calculated by dividing the net loss attributable for the year to shareholders of Evaxion Biotech A/S by the weighted average number of ordinary shares outstanding during the year. As net losses from continuing operations were recorded in the years 2018, 2019 and 2020, the dilutive potential shares are anti-dilutive for the earnings per share calculation.

 

 

 

 

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

    

2020

    

2019

    

2018

 

 

(USD in thousands, except share amounts and per share amounts)

Loss per share before and after dilution

 

 

 

 

 

  

 

 

  

Net loss attributable to shareholders of Evaxion Biotech A/S

 

$

(15,018)

 

$

(11,195)

 

$

(5,535)

Weighted-average number of ordinary shares outstanding

 

 

15,434,758

 

 

13,892,314

 

 

12,917,016

Loss per share before and after dilution

 

$

(0.97)

 

$

(0.81)

 

$

(0.43)

 

The following potential shares are anti-dilutive and are therefore excluded from the weighted average number of shares for the purpose of diluted loss per share:

 

 

 

 

 

 

 

 

 

    

December 31, 

 

    

2020

    

2019

    

2018

Warrants

 

2,228,076

 

2,059,128

 

1,674,324

Convertible Debt l

 

 —

 

 —

 

302,976

Convertible Debt 2

 

 —

 

 —

 

827,856